Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92

Morgan Stanley analyst Sean Laaman has maintained an Overweight rating on Disc Medicine (NASDAQ: IRON) and increased the price target from $90 to $92. This adjustment reflects the firm's positive outlook on the company's performance.